Nkarta, Inc.

Equities

NKTX

US65487U1088

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-10 pm EDT			5-day change	1st Jan Change
6.25 ^USD	-0.79%		-15.54%	-5.30%

May. 09	Nkarta, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Mar. 26	Canaccord Genuity Adjusts Nkarta's Price Target to $16 From $15, Keeps Buy Rating	MT

Nkarta, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023

March 21, 2024 at 04:01 pm EDT

Nkarta, Inc. reported earnings results for the fourth quarter and full year ended December 31, 2023. For the fourth quarter, the company reported net loss was USD 27.75 million compared to USD 32.58 million a year ago. Basic loss per share from continuing operations was USD 0.57 compared to USD 0.67 a year ago.
For the full year, net loss was USD 117.5 million compared to USD 113.84 million a year ago. Basic loss per share from continuing operations was USD 2.4 compared to USD 2.61 a year ago.

Latest news about Nkarta, Inc.

Nkarta, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09	CI
Canaccord Genuity Adjusts Nkarta's Price Target to $16 From $15, Keeps Buy Rating	Mar. 26	MT
HC Wainwright Adjusts Price Target on Nkarta to $22 From $20, Keeps Buy Rating	Mar. 25	MT
Nkarta Prices $240.1 Million Underwritten Offering	Mar. 25	MT
North American Morning Briefing : Tech in Focus on -2-	Mar. 25	DJ
Mizuho Securities Lowers Price Target on Nkarta to $25 From $31, Keeps Buy Rating	Mar. 22	MT
Mizuho Securities Cuts Price Target on Nkarta to $25 From $31, Maintains Buy Rating	Mar. 22	MT
HC Wainwright Adjusts Nkarta's Price Target to $20 From $22, Keeps Buy Rating	Mar. 22	MT
Raymond James Downgrades Nkarta to Outperform From Strong Buy, Price Target is $16	Mar. 22	MT
Nkarta Trims Q4 Loss -- Shares Up After Hours	Mar. 21	MT
Nkarta, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Mar. 21	CI
Mizuho Securities Adjusts Price Target on Nkarta to $31 From $9 as Lupus Nephritis Program Gets Attention, Keeps Buy Rating	Mar. 04	MT
Nkarta, Inc.(NasdaqGS:NKTX) dropped from NASDAQ Biotechnology Index	Dec. 15	CI
Nkarta, Inc. Presents NKX101 Clinical Data at the 2023 American Society of Hematology Annual Meeting & Exposition	Dec. 09	CI
Mizuho Securities Cuts Nkarta's Price Target to $9 From $15, Maintains Buy Rating	Nov. 16	MT
Nkarta, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
HC Wainwright Adjusts Price Target on Nkarta to $10 From $16, Keeps Buy Rating	23-10-18	MT
Raymond James Upgrades Nkarta to Strong Buy From Outperform, Price Target is $13	23-10-18	MT
North American Morning Briefing : Geopolitical -2-	23-10-18	DJ
Sector Update: Health Care Stocks Retreat in Late Afternoon	23-10-17	MT
Top Midday Gainers	23-10-17	MT
Sector Update: Health Care Stocks Mixed in Tuesday Afternoon Trading	23-10-17	MT
Lupus Therapeutics Announces Partnership to Support the Evaluation of Natural Killer (NK) Cell Therapy in Lupus Nephritis	23-10-17	CI
Nkarta's Stock Climbs 28% After FDA Approves Drug Application	23-10-17	DJ
Nkarta Says FDA Clears IND Application for Lupus Nephritis Treatment; Planning Cost Cuts to Extend Cash Runway	23-10-17	MT

Chart Nkarta, Inc.

Duration

Period

More charts

Company Profile

Nkarta, Inc. is a clinical-stage biopharmaceutical company advancing the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies for the treatment of patients with autoimmune diseases or hematologic malignancies. It is developing NKX019, a chimeric antigen receptor-natural killer (CAR NK) product candidate targeting the CD19 antigen and NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands. Both product candidates enable an on-demand, off-the-shelf approach involving scaled manufacturing to broaden patient access. Its NKX019 autoimmune program is based on the potential to eliminate the pathologic B cells that produce autoantibodies. Its NKX019 oncology program is based on the potential to treat a variety of B-cell malignancies by targeting the CD19 antigen that is reliably expressed on these types of cancerous cells. Its NKX101 program is designed to enhance the power of innate NK cell biology to detect and kill cancerous cells.

Sector

Biotechnology & Medical Research

Calendar

2024-06-12 - Annual General Meeting

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

6.25 USD

Average target price

19.12 USD

Spread / Average Target

+206.00%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
NKARTA, INC.	-5.30%	440M
VERTEX PHARMACEUTICALS INCORPORATED	+3.91%	109B
REGENERON PHARMACEUTICALS, INC.	+10.87%	105B
ARGENX SE	+1.28%	22.25B
BIONTECH SE	-13.14%	22.09B
GENMAB A/S	-7.05%	18.68B
WUXI APPTEC CO., LTD.	-38.36%	17.58B
BEIGENE, LTD.	-10.66%	16.85B
NEUROCRINE BIOSCIENCES, INC.	+3.75%	13.76B
SAREPTA THERAPEUTICS, INC.	+36.70%	12.46B

Bio Therapeutic Drugs